Last reviewed · How we verify
weekly cisplatin
Weekly cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.
Weekly cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis. Used for Various solid tumors (specific indications dependent on phase 3 trial design).
At a glance
| Generic name | weekly cisplatin |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Korea Cancer Center Hospital |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a DNA-damaging chemotherapy drug that binds to DNA and forms intrastrand and interstrand crosslinks, preventing DNA replication and transcription. This leads to cell cycle arrest and programmed cell death (apoptosis) in rapidly dividing cancer cells. The weekly dosing schedule is designed to improve tolerability compared to standard higher-dose cisplatin regimens while maintaining efficacy.
Approved indications
- Various solid tumors (specific indications dependent on phase 3 trial design)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (PHASE1)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (PHASE2)
- De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (PHASE2, PHASE3)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- weekly cisplatin CI brief — competitive landscape report
- weekly cisplatin updates RSS · CI watch RSS
- Korea Cancer Center Hospital portfolio CI